Member Info for BuenaVista

😳😂 Every BB has its BS'ing traders and naive investors. Lots of fun to be had watching.

Remember, do your own research and trust no one unless you personally know them and can judge their character. There are a lot of snakes and dogs out there.

Sunday will be truly massive. Folk have been hiking from Bideford and all points West just to be there. Special Security has been called up for crowd control and to impose strict backpack checks for hidden cameras and recording equiment. Dr Tap's AI-generated interactive 3D poster will be the sensation of the century! Believe me, I heard it first-hand from the Hurst Bot - and the number of deals that'll be signed over breakfast on Monday is just, literally, INCREDIBLE!😳

🤣🤣🤣HFH is a 🤡

In my inter years I worked on a farm for 5 years and could tell you exactly which cow had farted.

Isn't happening. Dr Tap has lost the poster. Don't panic! Don't panic!!

HL gets quotes from multiple MMs, so they say.

Looking forward to some good Avacta news as the parasite pub bore will then disappear as if by magic.

😂 That is funny.

I know it's perhaps a crazy idea, but maybe the shareholder presentations are prepared well in advance rather than on the day?

I know it's perhaps a crazy idea, but maybe the shareholder presentations are prepared well in advance rather than on the day?

That was followed 8 days later by this: https://avacta.com/esmo-poster-data-video-presentation-by-chris-coughlin/

This year the two conferences are back-to-back rather than having a month between them, so whether we get one or two explainers is anyone's guess.

Regular abstracts for the main ESMO Congress 2025 were published online on October 13, 2025, at 00:05 CEST and Avacta's for the Tap poster has been made available on this BB. Last year, Avacta didn't provide any RNS with details about the poster until the Monday after the Saturday presentation.

https://www.lse.co.uk/rns/AVCT/avacta-reported-updated-phase-1-data-of-ava6000-3pl7ovwfilmpzie.html

So, same again this year I'd guess.

@ArchBishopHolmes

"Pipeline prioritization with workforce and cost reduction initiatives

• Caribou is prioritizing its lead oncology programs, CB-010 and CB-011. Caribou is discontinuing the GALLOP Phase 1 trial of CB-010 for lupus prior to dosing the first patient. Caribou is also discontinuing the AMpLify Phase 1 clinical trial of CB-012 for relapsed or refractory acute myeloid leukemia (AML) as additional data would be needed to advance this program, taking time and resources that can be dedicated to CB-010 and CB-011. Patients treated in the AMpLify Phase 1 trial will continue to be followed as part of the company’s long-term follow up study. Additionally, the company is discontinuing preclinical research.

• The company is reducing its workforce by approximately 32%. Cash payments resulting from the reduction in force and strategic pipeline prioritization are estimated to be $2.5 to $3.5 million.

• These changes are expected to extend Caribou’s cash runway by one year, funding the company’s current operating plan into H2 2027, compared to into H2 2026 as previously reported."

https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-strategic-pipeline-prioritization

I should just add that for a Phase 1a trial, "assess treatment efficacy" isn't concerned with how well it works (with a statistically invalid 3 patients) so much as whether it works at all. As the progress of the 1st cohort has been reported patient by patient, it is highly likely that the DSMB will recommend progress to the next cohort and that may well already be baked into the share price. If the share price does rise on a positive recommendation by the DSMB, will that be a rerate or a spike? It's up to each investor/trader to choose, and act accordingly.

What's the beef here? A DSMB is a DSMB. There's no mystery about it. It is a requirement for a trial. Anyone can find out what it is. I was going to get the Wiki entry for it but just typing in 'data safety monitoring board' returned this, and more:

"A Data Safety Monitoring Board (DSMB) is an independent group of experts who monitor ongoing clinical trials to ensure patient safety and assess treatment efficacy. The DSMB reviews accumulated trial data, such as adverse effects and the progress of the study, and provides recommendations to the trial sponsor on whether the trial should continue, be modified, or be stopped early due to safety concerns or if the research question has been answered."

The DSMB will review the data, assess the safety to patients and either recommend progression to the next cohort or not. Whether progression to the 2nd of a possible four cohorts will lead to a rerating of the share price and consequent increase in Mcap is up to the market, taking into account many aspects concerning the science and funding.

I gather that it is intended that there will be (up to) four cohorts in Phase 1a, slated to finish in January 2027 - https://clinicaltrials.gov/study/NCT06786533 - which can only be a guestimate given the exploratory nature of Phase 1. Also surely more than one pediatric cohort will be needed as well now? Does Hemogenyx have funds to complete Phase 1a? Will there be a Phase 1b dose expansion?

Looking longterm, when do you think HG-CT-1 will receive regulatory approval? - What is the company's plan? I assume that, it being the way of clinical development for small biopharma companies, a lot more funding will be required in order to get there. Early days still, I know, but are plans for that funding in place already?

The way I understand it Bella: a buyer wants to do a worked order, the ?broker buys from sellers, only the sells show in the record, consequently the price drops, when the order is completed the buyer's whole trade is declared. Ore watt?

Older baron, watt is wrong with you're pee sea or eye pad or watt ever it is ewe use?

Well Derek, let's just wait until Prof Eggy has given it the once over and approved it.

If size were a problem then two dual payload drugs, each covering a key resistance mechanism of DNA damage repair as well as exatecan, could be given. That would have have greater flexibility of use (2 different drugs rather than 1 & 1+) in this case although there may be cases where three-in-one may be preferable. See? There are solutions if problems are talked through.